Dr. Christine Petti, a board-certified Los Angeles plastic surgeon, was one of six national authors of an FDA study that was recently presented, Multi-Center Evaluation for the Treatment of Cellulite Using a New Minimally Invasive Laser Approach, at the annual meeting of The American Society for Aesthetic Plastic Surgery (ASAPS) in Vancouver, Canada. This paper introduced Cellulaze, the Nd:YAG 1,440-nm wavelength laser, a minimally-invasive, single treatment for cellulite with results lasting one to two years post treatment. Dr. Petti says the goal of the research was to study the efficacy and safety of the 1440-nm laser and its ability to offer patients a less invasive and more effective method of removing cellulite.
Cellulaze utilizes fiberoptic laser energy in a three-step approach to safely and effectively attack the abnormal internal anatomy of cellulite. The fiberoptic technique permits a refined method directed at treating the lumpy fat, the dimpled and constricting, septal bands and the thin dermis of the skin, which are the key components of cellulite that leave women with an unfavorable appearance in the skin of the buttocks, thighs, abdomen and arms.
At the ASAPS 2012 Meeting, the results of the multi-center study were presented, in which 57 subjects in six clinical sites were treated for unwanted cellulite. After a single treatment, the procedure was well tolerated by all subjects, and any pain, swelling, numbness or other side effects were resolved within three months. The research also showed that the average satisfaction of physicians and patients, based on a six-point scale, was 5.4 and 4.7 respectively. Further studies of the changes at the anatomical level of the skin and fat where cellulite occurs demonstrated that there was a 25 percent increase in skin thickness and a 29 percent decrease in skin laxity that is maintained one year post treatment.